Skip to main content
PsyBio Therapeutics Corp. logo

PsyBio Therapeutics Corp. — Investor Relations & Filings

Ticker · PSYBF ISIN · CA74464R1000 LEI · 549300KO32JSWBZIZP18 TSXV Manufacturing
Open in API
Filings indexed 249 across all filing types
Latest filing 2021-08-30 Regulatory Filings
Country CA Canada
Listing TSXV PSYBF

About PsyBio Therapeutics Corp.

www.psybiolife.com

PsyBio Therapeutics Corp. is an intellectual property-driven biotechnology company focused on the discovery, design, and development of psycho-targeted therapeutics for mental and neurological conditions, including CNS disorders. The company develops a portfolio of novel psychoactive compounds and their analogues. A key differentiator is its proprietary platform utilizing genetically modified bacteria for the scalable, biosynthetic manufacturing of psychoactive molecules, such as tryptamines. PsyBio is actively engaged in preclinical studies and developing its own compounds, aiming to improve treatments for various psychologic and neurologic conditions.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Regulatory Filings
2021-08-30 English
News release - English.pdf
Regulatory Filings
2021-08-04 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the participation of PsyBio's CEO and CMO in a fireside chat at the LifeSci Partners Summer Symposium. It contains no financial data, no regulatory filings, no voting results, no management or board changes, no earnings or capital updates, and no detailed report or presentation. The document is a general corporate announcement about an upcoming event involving company executives. It does not fit into any specific financial report or regulatory filing category. Therefore, the best classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other categories.
2021-07-20 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing PsyBio Therapeutics Corp.'s uplisting to the OTCQB Venture Market. It discusses the trading symbols, market presence, and regulatory aspects related to the listing. There is no financial data, no detailed financial performance, no management discussion of results, no voting results, no audit information, no legal proceedings, no merger or acquisition details, and no executive compensation details. The document is primarily an announcement about a capital market event (uplisting) and related trading information. It does not contain financial statements or detailed financial analysis, so it is not an Annual Report, Interim Report, Earnings Release, or similar. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under Capital/Financing Update (CAP) as it relates to changes in the company's capital market listing and trading status, which is a financing/capital structure update.
2021-07-14 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the filing of a new provisional patent application by PsyBio Therapeutics Corp. It discusses the company's intellectual property portfolio, research and development activities, and forward-looking statements about future plans. There is no indication of financial data, regulatory filings, management changes, or shareholder voting results. The content is primarily an update on intellectual property and company progress, typical of a press release or regulatory announcement. It does not fit into categories like Annual Report, Earnings Release, or Legal Proceedings. Given the nature and length of the document, it is best classified as a Regulatory Filing (RNS), which serves as a fallback for miscellaneous announcements that do not fit other specific categories.
2021-07-13 English
Other.pdf
Legal Proceedings Report Classification · 90% confidence The document is a legal agreement amendment and license agreement between PsyBio Therapeutics, Inc. and Miami University. It details amendments to a Master Sponsored Agreement and a License Agreement related to research funding, intellectual property rights, and licensing terms. There are no financial statements, earnings data, regulatory certifications, or shareholder meeting materials. The content is primarily contractual and legal in nature, focusing on research sponsorship and licensing terms rather than financial reporting or corporate governance announcements. Therefore, it does not fit into categories like Annual Report, Earnings Release, Management Reports, or Regulatory Filings related to financial disclosures. The best fitting category is Legal Proceedings Report (LTR) as it covers significant legal agreements and contractual amendments involving the company.
2021-06-29 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.